Novartis Exelon Alzheimer's therapy approved in Switzerland in under four months.
Executive Summary
NOVARTIS TO LAUNCH EXELON IN SWISS MARKET IN LATE AUGUST following fast-track approval of the acetylcholinesterase inhibitor Alzheimer's therapy by Switzerland's health authority, Interkantonale Kontrollstelle fuer Heilmittel, July 31. Novartis filed for Exelon (rivastigmin) approval with IKS, FDA and the European Medicines Evaluation Agency April 7; the drug's swift Swiss approval could presage quick review elsewhere. Exelon is indicated in Switzerland to treat mild to moderately severe Alzheimer's disease.